** U.S. listed-shares of Merus NV MRUS.O up about 3% at $46.19 premarket
** Co has entered into a U.S. commercialization agreement with private biotech Partner Therapeutics
** Under the deal, Partner will assume full rights to U.S. commercialization of MRUS' gene-targeting cancer therapy zenocutuzumab or zeno for the treatment of NRG1 fusion-positive cancer in the United States
** In exchange, MRUS will receive an upfront payment and is eligible to receive milestones and high single-digit to low double-digit royalty payments tied to the therapy's future annual sales
** Last month, U.S. Food and Drug Administration extended the review of zeno to allow sufficient time to assess some recent information submitted by MRUS to the agency
** Co is seeking approval for zeno, which targets the NRG1 gene associated with progression of several tumors, for treatment of hard-to-treat types of lung and pancreatic cancers
** As of last close, MRUS was up ~57% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.